Multiple ganciclovir-resistant strains in a newborn with symptomatic congenital human cytomegalovirus infection

Journal of Clinical Virology

Volumn 54, Issue 1, 2012, Pages 86-88

  Campanini, Giulia ^a   Zavattoni, Maurizio ^a   Cristina, Emilio ^b   Gazzolo, Diego ^c   Stronati, Mauro ^a   Baldanti, Fausto ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c C Arrigo Children's Hospital   (Italy)

Author keywords

Congenital; Ganciclovir; HCMV mutations; Resistance

Indexed keywords

AMINO ACID; FOSCARNET; GANCICLOVIR; VALGANCICLOVIR;

ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; BLOOD; BODY WEIGHT; BRAIN CALCIFICATION; BRAIN VENTRICLE DILATATION; CASE REPORT; CYTOMEGALOVIRUS INFECTION; DRUG WITHDRAWAL; EVOKED BRAIN STEM AUDITORY RESPONSE; FEMALE; HEAD CIRCUMFERENCE; HEPATITIS; HEPATOSPLENOMEGALY; HUMAN; IMMATURITY; IMMUNE SYSTEM; INTRAUTERINE GROWTH RETARDATION; MICROCEPHALY; MUTATION; NEUTROPENIA; NEUTROPHIL; NEWBORN; PETECHIA; PRIORITY JOURNAL; SIDE EFFECT; SYMPTOMATIC CONGENITAL HUMAN CYTOMEGALOVIRUS INFECTION; THROMBOCYTOPENIA; URINE; VIRUS DETECTION; VIRUS ISOLATION; VIRUS LOAD; VIRUS STRAIN; WILD TYPE;

ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; COINFECTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GANCICLOVIR; GENOTYPE; HUMANS; INFANT, NEWBORN; MALE; MUTATION, MISSENSE; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PREGNANCY;

EID: 84861913251     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2012.01.020     Document Type: Article

References (13)

1. Gandhi R.S., Fernandez-Alvarez J.R., Rabe H. Management of congenital cytomegalovirus infection: an evidence-based approach. Acta Pediatr 2010, 99:509-518.
2. Amir J., Wolf D.G., Levy I. Treatment of symptomatic congenital cytomegalovirus infection with intravenous ganciclovir followed by long-term oral valganciclovir. Eur J Pediatr 2010, 169:1061-1067.
3. Kimberlin D.W., Lin C.Y., Sanchez P.J., Demmler G.J., Dankner W., Shelton M., et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr 2003, 143:16-25.
4. Oliver S.E., Cloud G.A., Sánchez P.J., Demmler G.J., Dankner W., Shelton M., et al. National Institute of Allergy, Infectious Diseases Collaborative Antiviral Study Group. Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system. J Clin Virol 2009, S4:22-26.
5. Baldanti F., Underwood M.R., Stanat S.C., Biron K.K., Chou S., Sarasini A., et al. Single amino acid changes in the polymerase confer Foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer Ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J Virol 1996, 70:1390-1395.
6. Lurain N.S., Weinberg A., Crumpacker C.S., Chou S. Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing. Antimicrob Agents Chemother 2001, 45:2775-2780. Adult AIDS Clinical Trials Group-CMV Laboratories.
7. Kampmann S.E., Schindele B., Apelt L., Bührer C., Garten L., Weizsaecker K., et al. Pyrosequencing allows the detection of emergent ganciclovir resistance mutations after HCMV infection. Med Microbiol Immunol 2011, 200:109-113.
8. Baldanti F., Lilleri D., Gerna G. Monitoring human cytomegalovirus infection in transplant recipients. J Clin Virol 2008, 41:237-241.
9. Smith I.L., Cherrington J.M., Jiles R.E., Fuller M.D., Freeman W.R., Spector S.A. High-level resistance of cytomegalovirus to ganciclovir is associated with alteration in both the UL97 and DNA polymerase genes. J Infect Dis 1997, 176:69-77.
10. Marfori J.E., Exner M.M., Marousek G.I., Chou S., Drew W.L. Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. J Clin Virol 2007, 38:120-125.
11. Wolf D.G., Yaniv I., Honigman A., Kassis I., Schonfeld T., Ashkenazi S. Early emergence of ganciclovir-resistant human cytomegalovirus strains in children with primary combined immunodeficiency. J Infect Dis 1998, 178:535-538.
12. Wolf D.G., Yaniv I., Ashkenazi S., Honigman A. Emergence of multiple human cytomegalovirus ganciclovir-resistant mutants with deletions and substitutions within the UL97 gene in a patient with severe combined immunodeficiency. Antimicrob Agents Chemother 2001, 45:593-595.
13. Stronati M, Lombardi G, Villani P, Garofoli F, Regazzi M. A review of the pharmacokinetic and pharmacodynamic properties of valganciclovir and its clinical use in newborns suffering from symptomatic congenital cytomegalovirus infection. Curr Drug Metab 2012; in press.